Photo of Achla Gupta

Achla Gupta

  • ASSISTANT PROFESSOR Pharmacology and Systems Therapeutics
Print ProfilePrint Profile


  • M.Phil., Aligarh Muslim University

  • Ph.D., Aligarh Muslim University


    Dr. Gupta is a member of the Devi Laboratory within the Department of Pharmacology and Systems Therapeutics.


My research interests include the investigation of G-protein coupled receptor heterodimerization/oligomerization using antibodies as tools. I have generated an antibody against mu-delta heterodimers using subtractive immunization. This antibody recognize mu-delta heterdimers by ELISA in vitro and as well as in vivo. I have also generated selective monoclonal antibodies against the N-terminal region of opioid receptors. We have used N-terminal selective antibodies to investigate the structural changes occurring during opioid receptor activation. Interestingly, antibody recognition was found to be modulated only by agonists and not antagonists in a dose-dependent manner. The antibodies were able to distinguish agonist-mediated conformational changes between wild-type and constitutively active mutant receptors. Based on these results, I have generated conformation-sensitive polyclonal antibodies against a similar region in the N-terminus of other members of the rhodopsin family (cannabinoid and adrenergic receptors). Interestingly, these antibodies were also able to recognize active conformations of the endogenous receptors. These antibodies provide a potential tool for identifying and characterizing new compounds of therapeutic interest.


Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, Lim M, Maillet E, Junek M, Cahill CM, Harkany T, Devi LA. Increased abundance of opioid receptor heteromers after chronic morphine administration. Sci Signal 2010 Jul; 3(131): ra54.

Moron JA, Gullapalli S, Taylor C, Gupta A, Gomes I, Devi LA. Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation. Neuropsychopharmacology 2010 Mar; 35(4): 955-966.

Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA. Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 2009 Sep; 23(9): 3020-3029.

Ellgren M, Artmann A, Tkalych O, Hansen HS, Devi LA, Hurd YL. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 2008 Nov; 18(11): 826-834.

Decaillot FM, Rozenfeld R, Gupta A, Devi LA. Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4. Proc Natl Acad Sci U S A 2008 Oct; 105(41): 16045-16050.

Gupta A, Heimann AS, Gomes I, Devi LA. Antibodies against G-protein coupled receptors: novel uses in screening and drug development. Comb Chem High Throughput Screen 2008 Jul; 11(6): 463-467.

Gupta A, Rozenfeld R, Gomes I, Raehal KM, Decaillot FM, Bohn LM, Devi LA. Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies. J Biol Chem 2008 Apr; 283(16): 10735-10744.

Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A 2007 Dec; 104(51): 20588-20593.

Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, Devi LA. Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 2007 Feb; 282(8): 5116-5124.

Gupta A, Devi LA. The use of receptor-specific antibodies to study G-protein-coupled receptors. Mt Sinai J Med 2006 Jul; 73(4): 673-681.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Gupta did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 19 Room 86
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-6545
Fax: 212-996-7214